Market News & Trends
Principia Achieves $10 Million in Additional Milestones
Principia Biopharma Inc. recently announced the achievement of $10 million in additional milestones related to successful development activities conducted by Principia as part of the…
EyePoint Pharmaceuticals Receives FDA Approval of YUTIQ
EyePoint Pharmaceuticals, Inc. recently announced the US FDA has approved YUTIQ (fluocinolone acetonide intravitreal implant) for the treatment of chronic non-infectious uveitis affecting the posterior segment…
Krystal Biotech Announces Positive Interim Results
Krystal Biotech, Inc. recently announced positive interim results from its ongoing placebo-controlled Phase 1/2 clinical trial of KB103. Two adult Recessive Dystrophic Epidermolysis Bullosa (RDEB),…
Importance of Cell Cycle & Cellular Senescence in the Placenta Discovered
Working with researchers from Stanford University and St. Anna Children's Cancer Research, researchers from Jürgen Pollheimer's laboratory at the Medical University of Vienna's Department of…
Athenex & Xiangxue Life Sciences Announce Preliminary Study Results
Athenex, Inc. recently announced that preliminary results of pilot studies in China in which patients received T-cell receptor affinity enhancing specific T-cell therapy (TAEST) showed encouraging…
Sarepta & Lysogene Announce Exclusive License Agreement
Sarepta Therapeutics, Inc. recently announced it has signed a license agreement with Lysogene (FR0013233475 - LYS), a pioneering biopharmaceutical company specializing in gene therapy targeting…
MeiraGTx Announces Acquisition of Vector Neurosciences
MeiraGTx Holdings Plc recently announced it has acquired Vector Neurosciences Inc. in an all-stock transaction. As a result of the acquisition, which was signed and…
Sitryx Launches With $30 Million to Develop Disease-Modifying Therapeutics
Sitryx recently announced it has closed its Series A financing round. The company, founded with seed funding from SV Health investors, raised a total of…
BioCorRx Announces Preliminary Agreement With VDM Biochemicals
BioCorRx Inc. recently announced the execution of a letter of intent (LOI) with VDM Biochemicals, Inc. (VDM), subject to execution of a definitive agreement, whereby…
Acquisitions Bolster PCI’s Global Position for Speed-to-Market
PCI Pharma Services’ presence at CPhI Worldwide 2018 (October 9-11, Madrid, Spain – Stand 3F10) highlighted considerable growth and expansion, including acquisition and integration of…
Amicus Therapeutics Enters Research & Development Collaboration
Amicus Therapeutics recently announced a major collaboration with the Gene Therapy Program in the Perelman School of Medicine at the University of Pennsylvania (Penn) to…
Wave Life Sciences to Develop Programs in Rare, Genetic Eye Diseases
Wave Life Sciences Ltd. recently announced plans to design and advance stereopure oligonucleotide therapeutics for the potential treatment of rare, inherited eye diseases. Wave’s research…
Ziopharm & Precigen Redefine Relationships, Announce New License Agreement
Ziopharm Oncology, Inc. and Precigen, Inc. recently announced a new definitive license agreement to replace all existing agreements between the companies that will provide Ziopharm with certain exclusive and non-exclusive rights to technology controlled by Precigen, Inc.
Pacific Biosciences Announces a New Paradigm in DNA Sequencing
Pacific Biosciences of California, Inc. recently announced major enhancements to its Sequel System, including a new version (6.0) of its software, new consumable reagents (3.0) and a new SMRT Cell (1M v3).
STRATA Skin Sciences Announces Completion of a Clinical Study
STRATA Skin Sciences recently announced the completion of a multi-center clinical study investigating the efficiency and efficacy of its FDA cleared Multi-Micro Dose (MMD) diagnostic…
Orphazyme Reports Encouraging Arimoclomol Clinical Trial Top-Line Data
Orphazyme A/S recently announced encouraging top-line results for its clinical Phase II/III trial with orally administered arimoclomol for the treatment of patients with Niemann-Pick disease…
Melinta Therapeutics & Menarini Group Enter Commercial Agreement
Melinta Therapeutics, Inc. and Menarini Group recently announced they have entered into an agreement under which Menarini will acquire the exclusive rights to co-develop and…
Dragonfly Therapeutics Announces New Multi-Target Collaboration With Merck
Dragonfly Therapeutics, Inc. recently announced a strategic collaboration with Merck, known as MSD outside the US and Canada, through a subsidiary, to discover, develop, and…
Hitachi Chemical Advanced Therapeutics Solutions Signs 3-Year Agreement With GSK
Hitachi Chemical Advanced Therapeutics Solutions, LLC recently announced it has signed a 3-year clinical manufacturing agreement with GSK. Under the agreement, HCATS will manufacture GSK’s…
Arzeda & BP Sign Collaborative Joint Development Agreement
Arzeda, The Protein Design Company, and BP recently announced a collaboration to develop a process for producing a renewable chemical with broad applications. This collaboration…